Implementing interventions to start HPV vaccination at age 9: Using the evidence we have

Area of Science:

• Public Health
• Vaccinology
• Cancer Prevention

Background:

• Human papillomavirus (HPV) vaccination is recommended for adolescents aged 11-12 but can start at age 9.
• On-time HPV vaccination by age 13 is effective in preventing HPV-related cancers.
• Current HPV vaccination coverage rates are lower than other adolescent vaccines.

Purpose of the Study:

• To explore the potential of initiating HPV vaccination at age 9 to improve coverage.
• To identify how existing evidence-based interventions can be adapted to promote earlier HPV vaccination.
• To leverage implementation science frameworks for intervention development and dissemination.

Main Methods:

• This study is a conceptual review and synthesis of existing literature and implementation science frameworks.
• It examines the benefits and challenges of starting HPV vaccination at age 9.
• It proposes a framework for adapting and developing interventions.

Main Results:

• Starting HPV vaccination at age 9 offers benefits such as increased time for series completion and enhanced cancer prevention messaging.
• There is limited knowledge on adapting current interventions for this earlier vaccination start.
• Implementation science provides a roadmap for developing and disseminating effective strategies.

Conclusions:

• Initiating HPV vaccination at age 9 is a promising strategy to boost coverage and prevent HPV cancers.
• Further research and adaptation of evidence-based interventions are crucial for successful implementation.
• Utilizing implementation science frameworks can accelerate the adoption of earlier HPV vaccination schedules.